News Summary

• Genus PLC (GENSF) achieved strong financial results with a 30% increase in group adjusted operating profit in constant currency.
• The company reported a significant milestone with the US FDA approval of their PRP gene edit, marking a major achievement in their R&D program.
• The ABS value acceleration program has delivered substantial benefits, with Phases I and II achieving over GBP21 million of annualized benefit.
• Genus is accelerating its joint venture formation in China, securing a $160 million gross cash payment and a $7.5 million milestone payment.